mRNA-2808

A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
166 patients (estimated)
Sponsors
ModernaTX, Inc.
Tags
GPRC5D, B-Cell Maturation Antigen (BCMA), FCRH5
Trial Type
Treatment
Last Update
SparkCures ID
2157
NCT Identifier
NCT07116616

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.